FDA Approves 8th Darzalex Faspro Indication for Myeloma Patients

FDA Approves 8th Darzalex Faspro Indication for Myeloma Patients

313498

FDA Approves 8th Darzalex Faspro Indication for Myeloma Patients

The U.S. Food and Drug Administration (FDA) has approved Darzalex Faspro (daratumumab and hyaluronidase), in combination with Kyprolis (carfilzomib) and the corticosteroid dexamethasone, for the treatment of adults with multiple myeloma who have received one to three lines of therapy. Darzalex Faspro is a subcutaneous, or under-the-skin, formulation of the Janssen laboratory-made therapy Darzalex (daratumumab), which is administered intravenously or into the vein. Compared with intravenous Darzalex, the subcutaneous formulation requires markedly less expertise to…

You must be logged in to read/download the full post.